{"gene":"CXCR2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2008,"finding":"CXCR2 knockdown alleviates both replicative and oncogene-induced senescence (OIS) in primary human fibroblasts, while ectopic CXCR2 expression induces premature senescence via a p53-dependent mechanism. Cells undergoing OIS secrete multiple CXCR2-binding chemokines (e.g., IL-8, GROα) regulated by NF-κB and C/EBPβ transcription factors, and coordinately upregulate CXCR2, establishing an autocrine/paracrine senescence-reinforcing secretory network.","method":"shRNA screen in primary human fibroblasts, ectopic overexpression, p53 pathway analysis, NF-κB/C/EBPβ transcription factor analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal loss-of-function and gain-of-function with defined molecular pathway (p53, NF-κB, C/EBPβ), replicated across multiple senescence models","pmids":["18555777"],"is_preprint":false},{"year":2003,"finding":"CXCR2 forms constitutive homodimers in a ligand-independent manner; the region between amino acids Ala-106 and Lys-163 is required for homodimerization. Truncated CXCR2 mutants that disrupt homodimerization impair receptor signaling and chemotaxis, establishing that CXCR2 functions as a dimer. CXCR1 does not dimerize with CXCR2.","method":"Co-immunoprecipitation of GFP- and V5-tagged CXCR2, truncation/deletion mutagenesis, functional assays (calcium signaling, chemotaxis) in HEK293 cells and cerebellar neurons","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with defined domain, co-IP in multiple cell types, functional consequences validated","pmids":["12888558"],"is_preprint":false},{"year":2005,"finding":"β-arrestin-2 is a negative regulator of CXCR2 signaling in vivo. Deletion of β-arrestin-2 in mice increases CXCR2-mediated Ca2+ mobilization, superoxide anion production, and GTPase activity in neutrophils, while decreasing receptor internalization. β-arrestin-2 deficiency also enhances neutrophil recruitment to CXCL1 in vivo and accelerates wound re-epithelialization.","method":"β-arrestin-2 knockout mouse model, Ca2+ mobilization assay, receptor internalization assay, GTPase assay, superoxide production assay, dorsal air pouch model, excisional wound healing model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts in vitro and in vivo, clear pathway placement","pmids":["16210646"],"is_preprint":false},{"year":2009,"finding":"CXCL8 monomer is more active than dimer for intracellular Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, and exocytosis via both CXCR1 and CXCR2. Receptor regulation differs: CXCR1 is more rapidly regulated (phosphorylation, desensitization, β-arrestin translocation, internalization) by the monomer, whereas CXCR2 responds similarly to both monomer and dimer for these regulatory activities. ERK phosphorylation is more sustained through CXCR2 than CXCR1.","method":"Trapped non-associating CXCL8 monomer (L25NMe) and non-dissociating dimer (R26C) tested on human neutrophils and RBL-2H3 cells stably expressing CXCR1 or CXCR2; Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, exocytosis, receptor phosphorylation, desensitization, β-arrestin translocation, internalization, ERK phosphorylation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — engineered ligand variants, multiple orthogonal functional assays, cell lines with defined receptor expression","pmids":["19667085"],"is_preprint":false},{"year":2010,"finding":"LASP-1 (LIM and SH3 protein-1) is a novel binding partner of CXCR2 that co-immunoprecipitates and co-localizes with CXCR2 at the leading edge of migrating cells. The LIM domain of LASP-1 directly binds the carboxy-terminal domain (CTD) of CXCR2, with Ile323-Leu324 of the conserved LKIL motif on CXCR2-CTD identified as the binding site. Disruption of this interaction inhibits CXCR2-mediated chemotaxis and focal adhesion turnover involving Src, paxillin, PAK1, p130CAS and ERK1/2.","method":"Proteomic co-immunoprecipitation from neutrophil-like dHL-60 cells, co-localization by microscopy, direct binding assay, site-directed and deletion mutagenesis, dominant negative and knockdown approaches, chemotaxis assays, focal adhesion kinase pathway analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding confirmed by mutagenesis of specific residues, co-IP plus functional knockout, multiple downstream pathway readouts","pmids":["20419088"],"is_preprint":false},{"year":2011,"finding":"IQGAP1 is a novel CXCR2-interacting protein identified by proteomics; amino acids 1-160 of IQGAP1 directly interact with the carboxyl-terminal domain of CXCR2. CXCR2 co-localizes with IQGAP1 at the leading edge of polarized neutrophils, and CXCL8 stimulation enhances IQGAP1 association with Cdc42, placing IQGAP1 as an essential component of the CXCR2 'chemosynapse'.","method":"Proteomics co-immunoprecipitation, direct binding assay (domain mapping), co-localization by immunofluorescence in human neutrophils and dHL-60 cells, CXCL8-stimulated signaling assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct domain interaction mapped, co-localization with functional context, single lab","pmids":["21876773"],"is_preprint":false},{"year":2014,"finding":"ADAM17 (TACE) mediates ligand-independent, irreversible CXCR2 shedding/down-regulation from the surface of mouse and human neutrophils upon overt neutrophil activation by non-ligand stimuli, but not upon chemokine ligand binding. Blocking ADAM17 reduces CXCR2 down-regulation on circulating neutrophils and enhances neutrophil recruitment during acute inflammation in vivo.","method":"Selective ADAM17 inhibitor, ADAM17 function-blocking antibody, ADAM17 gene-targeted mice, CXCR2 surface expression assay, in vivo acute inflammation model with CXCR2 inhibitor reversal","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacologic tools, multiple orthogonal approaches (inhibitor, antibody, KO mice), functional in vivo validation","pmids":["25412626"],"is_preprint":false},{"year":2017,"finding":"CCRL2, an atypical chemokine receptor, constitutively forms heterodimers with CXCR2 on neutrophils. CCRL2 heterodimerization regulates CXCR2 membrane expression and promotes CXCR2 functions including activation of β2-integrins. CCRL2-deficient mice show defective neutrophil recruitment and are protected in two models of inflammatory arthritis.","method":"Co-immunoprecipitation (heterodimer detection), CCRL2 knockout mouse model, in vitro β2-integrin activation assay, in vivo inflammatory arthritis models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP for heterodimerization, KO mouse phenotype in multiple disease models, functional β2-integrin readout","pmids":["28743719"],"is_preprint":false},{"year":2017,"finding":"CXCR2-driven activation of NLRP3 inflammasome in macrophages proceeds via a protein kinase Cμ-dependent integrin-linked kinase (ILK) pathway. CXCL1 and CXCL2 signaling through CXCR2 enhances NLRP3 inflammasome activation and subsequent bioactive IL-1β production; blocking ILK or PKCμ by siRNA or pharmacological inhibitors compromises inflammasome activation.","method":"siRNA knockdown of CXCR2, ILK, PKCμ; pharmacological inhibitors; NLRP3 inflammasome activation assays; in vivo mouse models of carrageenan-induced inflammation; in vivo M. tuberculosis infection model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (siRNA) and pharmacologic dissection of pathway, multiple orthogonal in vitro and in vivo models","pmids":["28739876"],"is_preprint":false},{"year":2008,"finding":"PPARγ transcriptionally activates CXCR2 expression in human macrophages by binding a PPAR response element (PPRE) in the CXCR2 promoter, increasing CXCR2 mRNA and membrane protein. PPARγ ligand-induced CXCR2 upregulation confers responsiveness to CXCR2 ligands (IL-8, GROβ) as measured by superoxide anion production.","method":"EMSA, ChIP, transient transfection/promoter assays, PPARγ ligand treatment of primary human macrophages; flow cytometry for membrane protein; superoxide production assay","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — PPRE binding confirmed by EMSA and ChIP, promoter transactivation assay, functional signaling readout","pmids":["18292390"],"is_preprint":false},{"year":2006,"finding":"PKCα activation in keratinocytes drives CXCR2-dependent neutrophil infiltration into the epidermis through NF-κB-dependent production of KC (CXCL1) and MIP-2 (CXCL2). Genetic ablation of CXCR2 in transgenic PKCα-overexpressing mice, or neutralizing antibodies against KC or MIP-2, prevents neutrophil infiltration. Systemic neutrophilia is mediated by G-CSF independently of CXCR2.","method":"Transgenic mouse model (K5-PKCα), CXCR2 knockout, neutralizing antibodies against KC/MIP-2, NF-κB pathway analysis, in vitro keratinocyte culture","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic CXCR2 ablation plus neutralizing antibody approaches, NF-κB mechanism established, in vivo and in vitro","pmids":["16964312"],"is_preprint":false},{"year":2006,"finding":"CXCR2 is constitutively expressed on oligodendrocytes in the CNS, while its ligand CXCL1 is induced on astrocytes by IL-1β. In human fetal astrocyte cultures, IL-1β stimulation drives high-level CXCL1 synthesis. This CXCR2/CXCL1 signaling provides a mechanism for recruitment of oligodendrocytes to areas of demyelination in multiple sclerosis.","method":"Immunohistochemistry of MS lesions, in vitro human fetal astrocyte and oligodendrocyte cultures, IL-1β stimulation assay, protein expression analysis","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — in vitro stimulation assay with human cells, IHC in human tissue, but no direct functional migration assay for oligodendrocytes","pmids":["16086366"],"is_preprint":false},{"year":2007,"finding":"CXCR2 expressed on resident lung cells (not on migrating mast cell progenitors themselves) is required for antigen-induced mast cell progenitor (MCp) recruitment to the lung and subsequent intraepithelial mast cell levels. CXCR2 deficiency reduces VCAM-1 transcripts and endothelial surface expression, linking CXCR2 signaling to regulation of endothelial VCAM-1 that is required for MCp migration.","method":"CXCR2-deficient mice, bone marrow reconstitution experiments (reciprocal BM transfers between WT and CXCR2-/- mice), anti-α4 integrin blocking mAb, VCAM-1 mRNA and surface protein quantification","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal bone marrow reconstitution establishes cell-specific requirement, VCAM-1 mechanism directly measured, multiple experimental controls","pmids":["18077323"],"is_preprint":false},{"year":2006,"finding":"CXCR2 and its ligands KC/CXCL1 and MIP-2/CXCL2/3 mediate neutrophil sequestration and lung injury in ventilator-induced lung injury (VILI). In vivo inhibition of CXCR2/CXC chemokine ligand interactions markedly reduces neutrophil sequestration and lung injury, confirmed in CXCR2-/- mice.","method":"Murine VILI model, in vivo anti-CXCR2 antibody blockade, CXCR2-/- mice, neutrophil counts, lung injury scoring","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout confirms pharmacologic blockade result, defined mechanistic pathway in vivo","pmids":["12464676"],"is_preprint":false},{"year":2006,"finding":"IL-8-mediated migration of liver cancer cells (Huh-7 and HepG2) occurs via both CXCR1 and CXCR2; pretreatment with anti-CXCR1 or anti-CXCR2 antibodies markedly inhibits IL-8-directed cell migration in vitro.","method":"In vitro wound healing assay, migration assay, receptor-blocking antibodies against CXCR1 and CXCR2","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single lab, receptor-blocking antibody approach, standard migration assays only","pmids":["31516616"],"is_preprint":false},{"year":2010,"finding":"CXCR2 promotes ovarian cancer cell cycle progression by modulating p21(waf1/cip1), cyclin D1, CDK6, CDK4, cyclin A, and cyclin B1; inhibits apoptosis by suppressing p-p53/Puma/Bcl-xS and activating Bcl-xL/Bcl-2; and stimulates angiogenesis by increasing VEGF and decreasing thrombospondin-1 through MAPK and NF-κB pathways. These effects were established by stable shRNA knockdown of CXCR2.","method":"Stable shRNA knockdown of CXCR2 in ovarian cancer cell lines, Western blot for cell cycle proteins and apoptosis markers, EMSA for NF-κB, ELISA for VEGF/thrombospondin-1, flow cytometry, mouse xenograft model","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable genetic knockdown with multiple downstream pathway readouts, in vivo validation, single lab","pmids":["20505188"],"is_preprint":false},{"year":2009,"finding":"CMV-encoded vCXCL1 (UL146 gene product) acts as a highly efficacious agonist on both CXCR1 and CXCR2 with affinities of 44 nM and 5.6 nM respectively, activating calcium mobilization, phosphatidylinositol turnover, and chemotaxis. vCXCL1 does not activate or block the other 16 classified human chemokine receptors.","method":"Calcium mobilization assay, competition binding against radiolabeled CXCL8, inositol triphosphate turnover, chemotaxis assay using CXCR1- and CXCR2-expressing CHO, 300.19, COS7, and L1.2 cells; panel of 18 human chemokine receptors screened","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — comprehensive receptor panel screen, multiple functional assays, quantitative binding affinities determined","pmids":["20044480"],"is_preprint":false},{"year":2019,"finding":"Extracellular DEK protein regulates hematopoietic stem cell (HSC) numbers and self-renewal through CXCR2 and heparan sulfate proteoglycans (HSPGs), with downstream activation of ERK1/2, AKT, and p38 MAPK. CXCR2-/- mice, CXCR2-blocking antibodies, and HSPG inhibitors all abolish DEK-mediated effects on HSC/HPC numbers.","method":"Cxcr2-/- mice, blocking CXCR2 antibodies, 3 different HSPG inhibitors, flow cytometry, transplantation assays, colony formation assays, phosphorylation assays (ERK1/2, AKT, p38 MAPK); DEK mutants lacking nuclear translocation signal or DNA-binding domain","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus multiple pharmacologic inhibitors, multiple orthogonal functional readouts including transplantation, signaling pathway mapped","pmids":["31107242"],"is_preprint":false},{"year":2016,"finding":"CXCR2 deficiency in the myeloid compartment (confirmed by bone marrow reconstitution) prevents CD11b+Ly6Ghi MDSC trafficking to tumor sites in rhabdomyosarcoma, establishing that CXCR2 on MDSCs mediates local immunosuppression that limits checkpoint blockade efficacy.","method":"CXCR2-deficient mice, anti-CXCR2 monoclonal antibody therapy, adoptive transfer/bone marrow reconstitution, flow cytometry for MDSC characterization, anti-PD1 combination therapy","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacologic CXCR2 ablation, adoptive transfer to define cell-autonomous requirement, defined immunosuppression phenotype","pmids":["24848257"],"is_preprint":false},{"year":2006,"finding":"CXCL8-induced chemotaxis via CXCR2 requires PI3K/Akt signaling and Cbl phosphorylation; Cbl and Akt regulate CXCR2-mediated chemotaxis. PI3K associates with Cbl upon CXCL8 stimulation. Kinase-dead Akt mutant decreases CXCR2-mediated chemotaxis and Cbl phosphorylation. Proteasome inhibition blocks CXCL8-induced internalization of CXCR2.","method":"CXCR2-overexpressing L1.2 cells, PI3K inhibitor (LY294002), tyrosine kinase inhibitor, proteasome inhibitors, overexpression of WT and mutant Cbl/Akt constructs, co-immunoprecipitation of PI3K p85 with Cbl, chemotaxis assay, internalization assay","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative mutants and pharmacologic inhibitors, co-IP, multiple functional readouts; single lab","pmids":["16798838"],"is_preprint":false},{"year":2019,"finding":"CXCL5 and CXCL8 activate CXCR2 on human brain endothelial cells (hCMEC/D3), causing Akt/PKB phosphorylation, redistribution of tight junction ZO-1, actin stress fiber formation, and decreased paracellular barrier function. CXCR2 expression is inflammation-inducible on brain endothelium, and selective CXCR2 antagonism (SB332235) partially prevents chemokine-induced tight junction disruption.","method":"Human cerebral microvascular endothelial cell line hCMEC/D3, recombinant CXCL5/CXCL8 treatment, real-time electrical impedance sensing for barrier function, immunofluorescence for ZO-1 and actin, Western blot for Akt phosphorylation, selective CXCR2 antagonist SB332235, IHC of human MS brain biopsies","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional barrier assay with pharmacologic antagonist rescue, mechanistic signaling (Akt) and structural (ZO-1) readouts, single lab","pmids":["30704100"],"is_preprint":false},{"year":2017,"finding":"CXCR2 in CXCR2(+)CD11b(+)Ly6Ghi MDSCs is required for their trafficking to pancreatic tumors; genetic ablation of CXCR2 abrogates metastasis, and combined CXCR2 inhibition with anti-PD1 significantly extends survival in established pancreatic cancer disease.","method":"Genetic ablation and pharmacologic inhibition of CXCR2 in KPC mouse model, neutrophil/MDSC depletion, flow cytometry for T cell infiltration, anti-PD1 combination therapy, survival analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacologic CXCR2 ablation, cell depletion, defined metastatic phenotype with mechanistic cell-type assignment","pmids":["27265504"],"is_preprint":false},{"year":2020,"finding":"Cxcl2 variants are more potent than Cxcl1 variants for Cxcr2 G-protein and β-arrestin receptor activation, while native Cxcl1 and its dimers bind heparan sulfate (HS) glycosaminoglycans with higher affinity than Cxcl2 variants. Peritoneal neutrophil recruitment cannot be solely attributed to Cxcr2 activation or GAG interactions alone, and their relationship is highly context-dependent.","method":"Cxcr2 G-protein and β-arrestin activity assays, GAG heparan sulfate binding assay, peritoneal neutrophil recruitment assay, flow cytometry for Cxcr2 and CD11b on neutrophils, engineered trapped dimer variants of Cxcl1 and Cxcl2","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — engineered ligand variants, in vitro receptor activity assays, in vivo recruitment assays with multiple conditions","pmids":["32881070"],"is_preprint":false},{"year":2017,"finding":"NMR and molecular dynamics reveal that CXCL7 forms heterodimers with CXCL1 and CXCL4 through packing interactions, while electrostatic repulsion disfavors CXCL7-CXCL8 heterodimer. A disulfide-trapped CXCL7-CXCL1 heterodimer is highly active in Ca2+ release assay via CXCR2 but GAG (heparin) binding to the heterodimer prevents receptor binding, suggesting GAG interactions regulate heterodimer function.","method":"Solution NMR spectroscopy, molecular dynamics simulation, disulfide-linked trapped heterodimer engineering, Ca2+ release assay (CXCR2 activation), heparin binding studies","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with engineered trapped heterodimer and functional Ca2+ assay, mechanistic insight into GAG vs receptor binding","pmids":["28368308"],"is_preprint":false},{"year":2019,"finding":"CXCR2 on bone marrow stroma (in addition to granulocytes) is involved in HSPC localization and egress; combined targeting of CXCR2 (agonist) and VLA4 integrin achieves rapid, synergistic mobilization of HSPCs including true HSCs in mice.","method":"CXCR2 agonist administration, VLA4 inhibitor, mechanistic studies using CXCR2 expressed on BM stroma vs granulocytes, HSPC flow cytometry, in vivo mobilization assays in mice","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mechanistic studies distinguishing stromal vs granulocyte CXCR2 contributions, single lab","pmids":["31085833"],"is_preprint":false},{"year":2019,"finding":"CXCR2 supports nociceptive sensitization after traumatic brain injury (TBI) through an epigenetic mechanism: TBI enhances association of the CXCR2 promoter with acetylated-H3K9 histone (assessed by ChIP), leading to spinal cord CXCR2 upregulation in neurons. Systemic or intrathecal CXCR2 antagonist (SCH527123) reverses hindpaw allodynia after TBI.","method":"Rat lateral fluid percussion TBI model, chromatin immunoprecipitation (ChIP) for H3K9 acetylation at CXCR2 promoter, CXCR2 antagonist (SCH527123) systemic and intrathecal administration, immunohistochemistry, Western blot, ELISA for CXCL1","journal":"Molecular pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishes epigenetic mechanism at CXCR2 promoter, pharmacologic antagonism confirms functional role, single lab","pmids":["28845733"],"is_preprint":false},{"year":2019,"finding":"CXCL1/CXCR2 signaling in the hippocampus contributes to chronic stress-induced depression in mice; CXCR2 inhibition (SB265610) prevents chronic stress-induced depression-like behaviors, inhibits GSK3β activity, blocks apoptosis pathways (reduced caspase-3, Bax), and restores BDNF and CREB expression. Intrahippocampal CXCL1 overexpression activates GSK3β and suppresses CREB/BDNF.","method":"Unpredictable chronic mild stress (UCMS) mouse model, intrahippocampal microinjection of lenti-CXCL1, CXCR2 inhibitor SB265610, GSK3β inhibitor AR-A014418, Western blot for caspase-3/Bax/CREB/BDNF, behavioral assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lentiviral gain-of-function and pharmacologic inhibition, defined molecular pathway (GSK3β-caspase-BDNF), single lab","pmids":["31034777"],"is_preprint":false},{"year":2019,"finding":"NMR structural analysis shows that tick salivary protein Evasin-3 disrupts the glycosaminoglycan-binding site of CXCL8 and inhibits CXCL8 interaction with CXCR2. Synthetic Evasin-3 variants effectively inhibit CXCL8-induced migration of polymorphonuclear neutrophils.","method":"Solution NMR spectroscopy of Evasin-3/CXCL8 complex, surface plasmon resonance for binding affinity, neutrophil migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure defines binding interface at CXCR2-binding site of CXCL8, functional validation by migration assay","pmids":["31235521"],"is_preprint":false},{"year":2023,"finding":"CXCL8/CXCR2 signaling drives bone marrow fibrosis in myelofibrosis; CXCL8 promotes proliferation and fitness of MF hematopoietic stem/progenitor cells in vitro. Genetic deletion of Cxcr2 in a murine MF model abrogates fibrosis and extends overall survival; pharmacologic CXCR1/2 pathway inhibition improves hematologic parameters, attenuates fibrosis, and synergizes with JAK inhibitor therapy.","method":"Single-cell transcriptomics, cytokine secretion studies in primary MF patient cells, hMPLW515L murine adoptive transfer model with Cxcr2 genetic deletion, pharmacologic CXCR1/2 inhibitor, JAK inhibitor combination, in vitro proliferation with exogenous CXCL8","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion in disease model, pharmacologic inhibition, patient primary cells, multiple orthogonal functional readouts","pmids":["36800567"],"is_preprint":false},{"year":2016,"finding":"CXCR2 signaling in KRASG12D-bearing pancreatic ductal cells mediates autocrine tumor cell proliferation; knockdown or pharmacological inhibition of CXCR2 reduces in vitro and in vivo tumor cell proliferation. Importantly, both genetic and pharmacological CXCR2 inhibition reduces KRAS protein levels, revealing a KRAS-CXCR2 feed-forward loop.","method":"CXCR2 knockdown in human KRAS(G12D)-bearing pancreatic duct-derived cells, CXCR2 antagonists (pharmacologic), in vitro proliferation assays, in vivo tumor growth, KRAS protein quantification by Western blot, Pdx1-cre;LSL-Kras(G12D) mouse model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacologic evidence for feed-forward loop, in vivo validation, single lab","pmids":["26771140"],"is_preprint":false},{"year":2022,"finding":"CXCR2 deficiency in Cxcr2 knockout mice decreases the percentage of mature neutrophils in spleen, increases aged CD62Llo CXCR4hi neutrophils in spleen, reduces phagocytic ability and reactive oxygen species production of spleen neutrophils, reduces F-actin and α-tubulin levels, and impairs ERK1/2, p38 MAPK, PI3K-AKT, NF-κB, TGFβ and IFNγ signaling pathways in neutrophils.","method":"Cxcr2 knockout mice, flow cytometry, phagocytosis assay, ROS production assay, F-actin/α-tubulin quantification, Western blot for signaling pathways","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comprehensive genetic KO analysis with multiple functional and signaling readouts, single lab","pmids":["36311783"],"is_preprint":false},{"year":2021,"finding":"CXCL2-CXCR2 signaling mediates colon cancer cell adhesion to extracellular matrix proteins (vitronectin, fibronectin, fibrinogen) in a CXCR2-dependent manner, and this adhesion requires αV integrin. In vivo, CXCR2 antagonism reduces peritoneal metastatic nodules by 70%, and αV integrin immunoneutralization reduces nodules by 69%, placing CXCL2-CXCR2 upstream of αV integrin in peritoneal metastasis.","method":"CXCR2 antagonist SB225002, αV integrin-blocking antibody, in vitro ECM adhesion assay, in vivo peritoneal metastasis mouse model (laparotomy + CT-26 cells), gene expression analysis of CXCL2","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and antibody-based pathway epistasis, in vitro mechanism with in vivo validation, single lab","pmids":["34115261"],"is_preprint":false},{"year":2020,"finding":"CXCL5-CXCR2 signaling constitutes a senescence-associated secretory phenotype (SASP) in aging mouse and human embryos; CXCL5 treatment of young mouse embryos decreases implantation rates and increases expression of aging markers (P53, P21, PAI-1, IL-6). Suppression of CXCL5-CXCR2 signaling in aging mouse embryos by neutralizing antibodies or receptor antagonist improves implantation rate and pregnancy outcomes.","method":"Microarray analysis of aging human blastocysts, mouse embryo culture with recombinant CXCL5, CXCR2 antagonist, CXCL5 neutralizing antibody, implantation assays, pregnancy and delivery outcomes, gene expression analysis","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and antibody inhibition with functional reproductive outcomes, aging marker quantification, single lab","pmids":["32959976"],"is_preprint":false},{"year":2017,"finding":"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2 (PTGS2). Mechanistically, CXCR2 promotes EMT, anti-apoptosis, and anti-senescence of breast cancer cells, with AKT1 and COX2 acting as downstream mediators inversely controlling these phenotypes.","method":"CXCR2 overexpression/knockdown in breast cancer cell lines, Western blot for AKT1, COX2, EMT markers, apoptosis markers, senescence assays, correlation with clinical tissue data","journal":"Cancer letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanism inferred from expression correlation and knockdown/overexpression without direct receptor-pathway reconstitution","pmids":["28964785"],"is_preprint":false}],"current_model":"CXCR2 is a G protein-coupled chemokine receptor that functions as a constitutive homodimer (requiring residues Ala-106 to Lys-163) and can heterodimerize with CCRL2 to regulate its surface expression and β2-integrin activation; upon binding ELR+ CXC chemokines (particularly CXCL8 monomer > dimer for most activities), it signals through Gα proteins to mobilize Ca2+, activate PI3K/AKT, ERK1/2, and p38 MAPK; β-arrestin-2 negatively regulates CXCR2 signaling by promoting receptor internalization, while ADAM17 mediates irreversible, ligand-independent CXCR2 shedding; intracellularly, CXCR2 assembles a 'chemosynapse' with scaffolding proteins LASP-1 (binding the LKIL motif on the C-terminal domain) and IQGAP1 to drive directed chemotaxis and focal adhesion turnover; CXCR2 is transcriptionally induced by PPARγ (via a PPRE in its promoter), NF-κB, and epigenetic H3K9 acetylation; it drives neutrophil recruitment to sites of inflammation, mediates MDSC trafficking to tumors, activates NLRP3 inflammasome via PKCμ-ILK, regulates endothelial VCAM-1 to control mast cell progenitor recruitment, reinforces cellular senescence via a p53-dependent autocrine/paracrine loop involving NF-κB/C/EBPβ-regulated CXCR2-binding chemokines, and supports KRAS-driven pancreatic cancer through an oncogene feed-forward loop."},"narrative":{"mechanistic_narrative":"CXCR2 is a G protein-coupled chemokine receptor for ELR+ CXC chemokines (CXCL1/2/5 and CXCL8/IL-8) that drives directed cell migration, most prominently neutrophil recruitment to sites of inflammation [PMID:12464676, PMID:16964312]. It functions as a constitutive, ligand-independent homodimer, with the region between Ala-106 and Lys-163 required for dimerization and for productive signaling and chemotaxis [PMID:12888558], and it additionally forms constitutive heterodimers with the atypical receptor CCRL2 that regulate its surface expression and enable β2-integrin activation [PMID:28743719]. Ligand discrimination is encoded at the protein level: the CXCL8 monomer is more active than the dimer for Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis and exocytosis, and CXCR2 produces more sustained ERK phosphorylation than CXCR1 [PMID:19667085], while CXCL2 variants are more potent than CXCL1 for G-protein and β-arrestin activation [PMID:32881070]. Downstream, CXCR2 signals through PI3K/Akt (with Cbl phosphorylation required for chemotaxis) and through ERK1/2 and p38 MAPK [PMID:16798838, PMID:36311783], and assembles an intracellular 'chemosynapse' in which LASP-1 binds the LKIL motif (Ile323-Leu324) of the receptor C-terminal domain and IQGAP1 (residues 1-160) engages the same CTD to couple the receptor to Cdc42, focal adhesion turnover and leading-edge polarization [PMID:20419088, PMID:21876773]. Receptor output is negatively regulated by β-arrestin-2, which promotes internalization and dampens Ca2+, superoxide and GTPase responses [PMID:16210646], and CXCR2 is irreversibly removed from the surface by ADAM17-mediated, ligand-independent shedding upon non-chemokine neutrophil activation [PMID:25412626]. Its expression is transcriptionally controlled by PPARγ via a promoter PPRE [PMID:18292390], by NF-κB-driven chemokine circuits [PMID:16964312], and by H3K9 acetylation at its promoter [PMID:28845733]. Through these mechanisms CXCR2 governs neutrophil and MDSC trafficking and immunosuppression in tumors [PMID:24848257, PMID:27265504], reinforces p53-dependent oncogene-induced senescence via an autocrine NF-κB/C/EBPβ chemokine loop [PMID:18555777], and sustains a KRAS-CXCR2 feed-forward loop in pancreatic cancer [PMID:26771140].","teleology":[{"year":2003,"claim":"Established the receptor's quaternary structure: it answered whether CXCR2 acts as a monomer or oligomer by showing it forms ligand-independent constitutive homodimers required for signaling.","evidence":"Co-IP of differentially tagged CXCR2 plus truncation mutagenesis mapping a Ala-106 to Lys-163 dimerization region, with Ca2+ and chemotaxis readouts in HEK293 cells and neurons","pmids":["12888558"],"confidence":"High","gaps":["No atomic-resolution structure of the dimer interface","Whether dimerization state is dynamically regulated by ligand or expression level not addressed"]},{"year":2005,"claim":"Placed β-arrestin-2 as the in vivo brake on CXCR2, resolving how the receptor is desensitized and internalized during neutrophil responses.","evidence":"β-arrestin-2 knockout mice with Ca2+, superoxide, GTPase, internalization assays and in vivo neutrophil recruitment/wound healing","pmids":["16210646"],"confidence":"High","gaps":["Phosphorylation sites recruiting β-arrestin-2 not mapped here","Distinction between arrestin scaffolding vs desensitization roles unresolved"]},{"year":2008,"claim":"Defined an upstream transcriptional input by showing PPARγ directly activates CXCR2 expression, linking nuclear receptor signaling to chemokine responsiveness.","evidence":"EMSA/ChIP of a PPRE in the CXCR2 promoter, promoter assays and superoxide readout in primary human macrophages","pmids":["18292390"],"confidence":"High","gaps":["Cooperating transcription factors at the promoter not defined","Physiological context driving PPARγ-dependent induction unclear"]},{"year":2008,"claim":"Connected CXCR2 to cell-autonomous senescence, showing it is both necessary and sufficient to reinforce oncogene-induced senescence through a p53-dependent autocrine chemokine network.","evidence":"shRNA screen and ectopic overexpression in primary human fibroblasts with p53 and NF-κB/C/EBPβ pathway analysis","pmids":["18555777"],"confidence":"High","gaps":["Direct receptor-to-p53 signaling intermediates not mapped","Whether autocrine chemokine identity determines senescence strength untested"]},{"year":2009,"claim":"Showed that ligand oligomeric state encodes signaling bias, distinguishing CXCR2 from CXCR1 in regulation and ERK kinetics.","evidence":"Trapped CXCL8 monomer (L25NMe) and dimer (R26C) variants on neutrophils and RBL-2H3 cells expressing CXCR1 or CXCR2, multiple functional and regulatory assays","pmids":["19667085"],"confidence":"High","gaps":["Structural basis for differential CXCR1/CXCR2 regulation not resolved","In vivo relevance of monomer/dimer bias not addressed"]},{"year":2010,"claim":"Identified the molecular scaffold of directed migration by mapping a direct LASP-1 interaction to the CXCR2 C-terminal LKIL motif controlling chemotaxis and focal adhesion turnover.","evidence":"Proteomic co-IP, direct binding with residue-level mutagenesis (Ile323-Leu324), co-localization and FAK pathway analysis in dHL-60 neutrophil-like cells","pmids":["20419088"],"confidence":"High","gaps":["Stoichiometry of the chemosynapse not defined","Whether LASP-1 binding is regulated by receptor phosphorylation unknown"]},{"year":2011,"claim":"Extended the chemosynapse model by adding IQGAP1 as a direct CTD partner linking the receptor to Cdc42 at the leading edge.","evidence":"Proteomic co-IP, domain mapping (IQGAP1 aa 1-160), co-localization and CXCL8-stimulated Cdc42 association in human neutrophils","pmids":["21876773"],"confidence":"Medium","gaps":["Single-lab finding without reciprocal validation in other systems","Order of LASP-1 vs IQGAP1 assembly on the CTD unclear"]},{"year":2014,"claim":"Defined an irreversible, ligand-independent off-switch by identifying ADAM17 as the protease that sheds CXCR2 upon non-chemokine neutrophil activation.","evidence":"ADAM17 inhibitor, blocking antibody and gene-targeted mice with surface expression and in vivo acute inflammation readouts","pmids":["25412626"],"confidence":"High","gaps":["Cleavage site on CXCR2 not mapped","Signals triggering ADAM17 activation toward CXCR2 not defined"]},{"year":2016,"claim":"Demonstrated cell-autonomous CXCR2 requirement in myeloid MDSCs for tumor trafficking and immunosuppression that limits checkpoint blockade.","evidence":"CXCR2-deficient mice, anti-CXCR2 antibody, bone marrow reconstitution and anti-PD1 combination in rhabdomyosarcoma","pmids":["24848257"],"confidence":"High","gaps":["Chemokine ligands recruiting MDSCs not specified here","Whether MDSC CXCR2 signaling differs mechanistically from neutrophil signaling unaddressed"]},{"year":2017,"claim":"Identified CCRL2 heterodimerization as a regulator of CXCR2 surface expression and β2-integrin activation, broadening the receptor's interaction repertoire.","evidence":"Co-IP, CCRL2 knockout mice, in vitro β2-integrin activation and inflammatory arthritis models","pmids":["28743719"],"confidence":"High","gaps":["Heterodimer interface not mapped","Mechanism by which CCRL2 alters CXCR2 signaling bias unresolved"]},{"year":2017,"claim":"Linked CXCR2 to innate inflammasome output by placing PKCμ-ILK between the receptor and NLRP3 activation in macrophages.","evidence":"siRNA and pharmacologic inhibition of CXCR2/ILK/PKCμ with inflammasome assays and in vivo carrageenan and M. tuberculosis models","pmids":["28739876"],"confidence":"High","gaps":["Direct biochemical link from receptor to PKCμ not established","G protein coupling to this pathway not defined"]},{"year":2016,"claim":"Revealed a KRAS-CXCR2 feed-forward loop in pancreatic ductal cells where receptor inhibition lowers KRAS protein, defining an oncogenic autocrine circuit.","evidence":"CXCR2 knockdown and antagonists in KRAS(G12D) pancreatic duct cells, KRAS Western blot and Pdx1-cre;LSL-Kras(G12D) mice","pmids":["26771140"],"confidence":"Medium","gaps":["Mechanism by which CXCR2 stabilizes KRAS protein unknown","Single-lab finding without orthogonal confirmation"]},{"year":2019,"claim":"Provided structural insight into ligand regulation by GAGs, showing chemokine heterodimer formation and heparin binding modulate CXCR2 receptor engagement.","evidence":"Solution NMR and MD with disulfide-trapped CXCL7-CXCL1 heterodimer and Ca2+ release assays; separately, Evasin-3 NMR mapping of the CXCL8 GAG/CXCR2-binding site with neutrophil migration assays","pmids":["28368308","31235521"],"confidence":"High","gaps":["No co-structure of chemokine bound to CXCR2 itself","In vivo significance of heterodimer-GAG competition not tested"]},{"year":2019,"claim":"Placed CXCR2 in hematopoietic stem cell regulation, showing extracellular DEK acts through CXCR2 and HSPGs to control HSC self-renewal via ERK/AKT/p38.","evidence":"Cxcr2-/- mice, blocking antibodies, HSPG inhibitors, transplantation, colony and phosphorylation assays with DEK mutants","pmids":["31107242"],"confidence":"High","gaps":["Whether DEK is a direct CXCR2 agonist not biochemically established","Relative contribution of HSPG vs CXCR2 binding not separated"]},{"year":2023,"claim":"Established CXCR2 as a disease driver in myelofibrosis, where CXCL8/CXCR2 promotes malignant HSPC fitness and fibrosis and synergizes with JAK inhibition.","evidence":"Single-cell transcriptomics, primary MF patient cells, hMPLW515L murine model with Cxcr2 deletion, CXCR1/2 and JAK inhibitor combination","pmids":["36800567"],"confidence":"High","gaps":["Cell-of-origin for pathogenic CXCR2 signaling not fully resolved","Direct downstream effectors of fibrosis induction not defined"]},{"year":null,"claim":"How the distinct CXCR2 signaling outputs (G-protein vs β-arrestin, homodimer vs CCRL2 heterodimer, monomer vs dimer ligand) are integrated to specify divergent cellular outcomes — chemotaxis, senescence, inflammasome activation, KRAS stabilization — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of CXCR2 in its dimeric/heterodimeric states","Biased agonism rules across ligands not systematically defined","Mechanistic links from receptor to non-canonical outputs (KRAS protein levels, p53) not biochemically traced"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,16,22]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,6,9]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,8,13,18]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[21,28,29]}],"complexes":["CXCR2 homodimer","CXCR2-CCRL2 heterodimer","CXCR2 chemosynapse (with LASP-1 and IQGAP1)"],"partners":["CCRL2","LASP1","IQGAP1","ARRB2","ADAM17","CDC42","CXCL8","CXCL1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25025","full_name":"C-X-C chemokine receptor type 2","aliases":["CDw128b","GRO/MGSA receptor","High affinity interleukin-8 receptor B","IL-8R B","IL-8 receptor type 2"],"length_aa":360,"mass_kda":40.8,"function":"Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor (PubMed:1891716). Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:8662698). Binds to IL-8 with high affinity. Also binds with high affinity to CXCL3, GRO/MGSA and NAP-2 (PubMed:1891716). Involved in the homeostatic wound healing response to tissue injury, a multistep cascade that guides neutrophil migration to necrotic sites while avoiding collateral damage of healthy tissues. Signals intravascular neutrophil chemotaxis to the injury site","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P25025/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCR2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCR2","total_profiled":1310},"omim":[{"mim_id":"619407","title":"WHIM SYNDROME 2; WHIMS2","url":"https://www.omim.org/entry/619407"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"608678","title":"INTERLEUKIN 33; IL33","url":"https://www.omim.org/entry/608678"},{"mim_id":"604837","title":"PROSTAGLANDIN D2 RECEPTOR 2; PTGDR2","url":"https://www.omim.org/entry/604837"},{"mim_id":"603028","title":"TOLL-LIKE RECEPTOR 2; TLR2","url":"https://www.omim.org/entry/603028"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Microtubules","reliability":"Additional"},{"location":"Mitotic spindle","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":25.7},{"tissue":"lymphoid tissue","ntpm":40.8}],"url":"https://www.proteinatlas.org/search/CXCR2"},"hgnc":{"alias_symbol":["CMKAR2","CD182"],"prev_symbol":["IL8RB"]},"alphafold":{"accession":"P25025","domains":[{"cath_id":"1.20.1070.10","chopping":"45-330","consensus_level":"high","plddt":85.5486,"start":45,"end":330}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25025","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25025-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25025-F1-predicted_aligned_error_v6.png","plddt_mean":79.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCR2","jax_strain_url":"https://www.jax.org/strain/search?query=CXCR2"},"sequence":{"accession":"P25025","fasta_url":"https://rest.uniprot.org/uniprotkb/P25025.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25025/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25025"}},"corpus_meta":[{"pmid":"18555777","id":"PMC_18555777","title":"Chemokine signaling via the CXCR2 receptor reinforces senescence.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18555777","citation_count":1448,"is_preprint":false},{"pmid":"27265504","id":"PMC_27265504","title":"CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.","date":"2016","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/27265504","citation_count":742,"is_preprint":false},{"pmid":"32289253","id":"PMC_32289253","title":"CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32289253","citation_count":655,"is_preprint":false},{"pmid":"24848257","id":"PMC_24848257","title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24848257","citation_count":649,"is_preprint":false},{"pmid":"12464676","id":"PMC_12464676","title":"Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12464676","citation_count":387,"is_preprint":false},{"pmid":"19904283","id":"PMC_19904283","title":"Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.","date":"2009","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19904283","citation_count":372,"is_preprint":false},{"pmid":"22922255","id":"PMC_22922255","title":"Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22922255","citation_count":330,"is_preprint":false},{"pmid":"35700773","id":"PMC_35700773","title":"METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer.","date":"2022","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/35700773","citation_count":211,"is_preprint":false},{"pmid":"19026683","id":"PMC_19026683","title":"CXCR2 antagonists for the treatment of pulmonary disease.","date":"2008","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19026683","citation_count":186,"is_preprint":false},{"pmid":"33814009","id":"PMC_33814009","title":"Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33814009","citation_count":178,"is_preprint":false},{"pmid":"9973513","id":"PMC_9973513","title":"Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9973513","citation_count":174,"is_preprint":false},{"pmid":"35477863","id":"PMC_35477863","title":"CXCR2 inhibition enables NASH-HCC immunotherapy.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/35477863","citation_count":169,"is_preprint":false},{"pmid":"22936934","id":"PMC_22936934","title":"CXCR2: From Bench to Bedside.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22936934","citation_count":160,"is_preprint":false},{"pmid":"19667085","id":"PMC_19667085","title":"Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19667085","citation_count":159,"is_preprint":false},{"pmid":"25810490","id":"PMC_25810490","title":"IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25810490","citation_count":158,"is_preprint":false},{"pmid":"20505188","id":"PMC_20505188","title":"CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20505188","citation_count":155,"is_preprint":false},{"pmid":"28587921","id":"PMC_28587921","title":"CXCL1/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28587921","citation_count":130,"is_preprint":false},{"pmid":"28739876","id":"PMC_28739876","title":"CXCL1 and CXCL2 Regulate NLRP3 Inflammasome Activation via G-Protein-Coupled Receptor CXCR2.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28739876","citation_count":129,"is_preprint":false},{"pmid":"35216283","id":"PMC_35216283","title":"CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35216283","citation_count":121,"is_preprint":false},{"pmid":"32881070","id":"PMC_32881070","title":"Neutrophil recruitment by chemokines Cxcl1/KC and Cxcl2/MIP2: Role of Cxcr2 activation and glycosaminoglycan interactions.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32881070","citation_count":119,"is_preprint":false},{"pmid":"10852110","id":"PMC_10852110","title":"Interleukin-8 and its receptor CXCR2 in atherosclerosis.","date":"2000","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/10852110","citation_count":116,"is_preprint":false},{"pmid":"21343381","id":"PMC_21343381","title":"Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer.","date":"2011","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21343381","citation_count":112,"is_preprint":false},{"pmid":"16458421","id":"PMC_16458421","title":"Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16458421","citation_count":111,"is_preprint":false},{"pmid":"16086366","id":"PMC_16086366","title":"Role for CXCR2 and CXCL1 on glia in multiple sclerosis.","date":"2006","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/16086366","citation_count":110,"is_preprint":false},{"pmid":"27678262","id":"PMC_27678262","title":"Genetic and Pharmacologic Inhibition of the Chemokine Receptor CXCR2 Prevents Experimental Hypertension and Vascular Dysfunction.","date":"2016","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/27678262","citation_count":105,"is_preprint":false},{"pmid":"19401689","id":"PMC_19401689","title":"CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19401689","citation_count":95,"is_preprint":false},{"pmid":"28964785","id":"PMC_28964785","title":"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28964785","citation_count":94,"is_preprint":false},{"pmid":"12888558","id":"PMC_12888558","title":"Ligand-independent CXCR2 dimerization.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12888558","citation_count":88,"is_preprint":false},{"pmid":"28743719","id":"PMC_28743719","title":"The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28743719","citation_count":87,"is_preprint":false},{"pmid":"28481874","id":"PMC_28481874","title":"A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28481874","citation_count":85,"is_preprint":false},{"pmid":"29383101","id":"PMC_29383101","title":"CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29383101","citation_count":85,"is_preprint":false},{"pmid":"22719179","id":"PMC_22719179","title":"CXCR2 in acute lung injury.","date":"2012","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22719179","citation_count":83,"is_preprint":false},{"pmid":"18077323","id":"PMC_18077323","title":"Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18077323","citation_count":80,"is_preprint":false},{"pmid":"22445294","id":"PMC_22445294","title":"Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?","date":"2012","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/22445294","citation_count":79,"is_preprint":false},{"pmid":"17030560","id":"PMC_17030560","title":"Exercise induces interleukin-8 receptor (CXCR2) expression in human skeletal muscle.","date":"2006","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17030560","citation_count":78,"is_preprint":false},{"pmid":"18838863","id":"PMC_18838863","title":"Control of senescence by CXCR2 and its ligands.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18838863","citation_count":75,"is_preprint":false},{"pmid":"15598788","id":"PMC_15598788","title":"Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma.","date":"2004","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15598788","citation_count":75,"is_preprint":false},{"pmid":"16210646","id":"PMC_16210646","title":"Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210646","citation_count":74,"is_preprint":false},{"pmid":"30926789","id":"PMC_30926789","title":"Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30926789","citation_count":70,"is_preprint":false},{"pmid":"16964312","id":"PMC_16964312","title":"CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16964312","citation_count":69,"is_preprint":false},{"pmid":"19276354","id":"PMC_19276354","title":"A role for CXCR2 in senescence, but what about in cancer?","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19276354","citation_count":65,"is_preprint":false},{"pmid":"37872025","id":"PMC_37872025","title":"CXCR2 chemokine receptor - a master regulator in cancer and physiology.","date":"2023","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37872025","citation_count":63,"is_preprint":false},{"pmid":"27222476","id":"PMC_27222476","title":"CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27222476","citation_count":61,"is_preprint":false},{"pmid":"20044480","id":"PMC_20044480","title":"The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20044480","citation_count":60,"is_preprint":false},{"pmid":"32453916","id":"PMC_32453916","title":"CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32453916","citation_count":59,"is_preprint":false},{"pmid":"25772246","id":"PMC_25772246","title":"Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25772246","citation_count":58,"is_preprint":false},{"pmid":"30236892","id":"PMC_30236892","title":"CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30236892","citation_count":56,"is_preprint":false},{"pmid":"20419088","id":"PMC_20419088","title":"LIM and SH3 protein-1 modulates CXCR2-mediated cell migration.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20419088","citation_count":55,"is_preprint":false},{"pmid":"25950520","id":"PMC_25950520","title":"CXCR2 inhibition suppresses acute and chronic pancreatic inflammation.","date":"2015","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25950520","citation_count":54,"is_preprint":false},{"pmid":"18552386","id":"PMC_18552386","title":"Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18552386","citation_count":51,"is_preprint":false},{"pmid":"36800567","id":"PMC_36800567","title":"CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36800567","citation_count":50,"is_preprint":false},{"pmid":"35908611","id":"PMC_35908611","title":"Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases.","date":"2022","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35908611","citation_count":50,"is_preprint":false},{"pmid":"20230195","id":"PMC_20230195","title":"Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20230195","citation_count":50,"is_preprint":false},{"pmid":"23425074","id":"PMC_23425074","title":"CXCR2: a target for pancreatic cancer treatment?","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23425074","citation_count":47,"is_preprint":false},{"pmid":"33785307","id":"PMC_33785307","title":"CXCL5/CXCR2 modulates inflammation-mediated neural repair after optic nerve injury.","date":"2021","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33785307","citation_count":46,"is_preprint":false},{"pmid":"30407218","id":"PMC_30407218","title":"The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.","date":"2019","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30407218","citation_count":44,"is_preprint":false},{"pmid":"29117499","id":"PMC_29117499","title":"Preclinical chorioamnionitis dysregulates CXCL1/CXCR2 signaling throughout the placental-fetal-brain axis.","date":"2017","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29117499","citation_count":44,"is_preprint":false},{"pmid":"31034777","id":"PMC_31034777","title":"The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress-induced depression in mice.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31034777","citation_count":43,"is_preprint":false},{"pmid":"38492894","id":"PMC_38492894","title":"Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy.","date":"2024","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/38492894","citation_count":42,"is_preprint":false},{"pmid":"35981418","id":"PMC_35981418","title":"CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35981418","citation_count":40,"is_preprint":false},{"pmid":"20018298","id":"PMC_20018298","title":"Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma.","date":"2009","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/20018298","citation_count":40,"is_preprint":false},{"pmid":"31085833","id":"PMC_31085833","title":"Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31085833","citation_count":40,"is_preprint":false},{"pmid":"34115261","id":"PMC_34115261","title":"CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.","date":"2021","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/34115261","citation_count":39,"is_preprint":false},{"pmid":"32391006","id":"PMC_32391006","title":"Structural Insights Into How Proteoglycans Determine Chemokine-CXCR1/CXCR2 Interactions: Progress and Challenges.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32391006","citation_count":37,"is_preprint":false},{"pmid":"31927212","id":"PMC_31927212","title":"The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.","date":"2020","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/31927212","citation_count":37,"is_preprint":false},{"pmid":"25511644","id":"PMC_25511644","title":"Host Cxcr2-dependent regulation of mammary tumor growth and metastasis.","date":"2014","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/25511644","citation_count":37,"is_preprint":false},{"pmid":"26771140","id":"PMC_26771140","title":"CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26771140","citation_count":37,"is_preprint":false},{"pmid":"17299604","id":"PMC_17299604","title":"CXCR2--the receptor to hit?","date":"2006","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/17299604","citation_count":36,"is_preprint":false},{"pmid":"31516616","id":"PMC_31516616","title":"Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31516616","citation_count":36,"is_preprint":false},{"pmid":"27297979","id":"PMC_27297979","title":"TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27297979","citation_count":35,"is_preprint":false},{"pmid":"37247498","id":"PMC_37247498","title":"The role of CXCL1/CXCR2 axis in neurological diseases.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37247498","citation_count":34,"is_preprint":false},{"pmid":"10747307","id":"PMC_10747307","title":"Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells.","date":"2000","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10747307","citation_count":34,"is_preprint":false},{"pmid":"24965032","id":"PMC_24965032","title":"The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour.","date":"2014","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24965032","citation_count":34,"is_preprint":false},{"pmid":"36780833","id":"PMC_36780833","title":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36780833","citation_count":33,"is_preprint":false},{"pmid":"31107242","id":"PMC_31107242","title":"Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31107242","citation_count":33,"is_preprint":false},{"pmid":"25412626","id":"PMC_25412626","title":"Regulation of CXCR2 expression and function by a disintegrin and metalloprotease-17 (ADAM17).","date":"2014","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/25412626","citation_count":33,"is_preprint":false},{"pmid":"32959976","id":"PMC_32959976","title":"CXCL5-CXCR2 signaling is a senescence-associated secretory phenotype in preimplantation embryos.","date":"2020","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/32959976","citation_count":33,"is_preprint":false},{"pmid":"28845733","id":"PMC_28845733","title":"The Chemokine Receptor CXCR2 Supports Nociceptive Sensitization after Traumatic Brain Injury.","date":"2017","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/28845733","citation_count":32,"is_preprint":false},{"pmid":"32800946","id":"PMC_32800946","title":"KLF2 regulates neutrophil migration by modulating CXCR1 and CXCR2 in asthma.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32800946","citation_count":32,"is_preprint":false},{"pmid":"33453178","id":"PMC_33453178","title":"Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis.","date":"2021","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33453178","citation_count":30,"is_preprint":false},{"pmid":"30704100","id":"PMC_30704100","title":"Human Brain Endothelial CXCR2 is Inflammation-Inducible and Mediates CXCL5- and CXCL8-Triggered Paraendothelial Barrier Breakdown.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30704100","citation_count":30,"is_preprint":false},{"pmid":"32079335","id":"PMC_32079335","title":"CXCL1/CXCR2 Paracrine Axis Contributes to Lung Metastasis in Osteosarcoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32079335","citation_count":30,"is_preprint":false},{"pmid":"28368308","id":"PMC_28368308","title":"Chemokine CXCL7 Heterodimers: Structural Insights, CXCR2 Receptor Function, and Glycosaminoglycan Interactions.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28368308","citation_count":30,"is_preprint":false},{"pmid":"16798838","id":"PMC_16798838","title":"Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis.","date":"2006","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16798838","citation_count":28,"is_preprint":false},{"pmid":"31001130","id":"PMC_31001130","title":"CXCR2 Blockade Mitigates Neural Cell Injury Following Preclinical Chorioamnionitis.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31001130","citation_count":28,"is_preprint":false},{"pmid":"34831316","id":"PMC_34831316","title":"Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34831316","citation_count":28,"is_preprint":false},{"pmid":"37062329","id":"PMC_37062329","title":"Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37062329","citation_count":26,"is_preprint":false},{"pmid":"31604030","id":"PMC_31604030","title":"Cell-specific regulatory effects of CXCR2 on cholestatic liver injury.","date":"2019","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31604030","citation_count":25,"is_preprint":false},{"pmid":"32812337","id":"PMC_32812337","title":"Selective blocking of CXCR2 prevents and reverses atrial fibrillation in spontaneously hypertensive rats.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32812337","citation_count":25,"is_preprint":false},{"pmid":"39397001","id":"PMC_39397001","title":"Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39397001","citation_count":24,"is_preprint":false},{"pmid":"18292390","id":"PMC_18292390","title":"Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18292390","citation_count":24,"is_preprint":false},{"pmid":"21876773","id":"PMC_21876773","title":"IQGAP1 is a novel CXCR2-interacting protein and essential component of the \"chemosynapse\".","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21876773","citation_count":24,"is_preprint":false},{"pmid":"31235521","id":"PMC_31235521","title":"Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31235521","citation_count":24,"is_preprint":false},{"pmid":"19057948","id":"PMC_19057948","title":"CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.","date":"2009","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19057948","citation_count":23,"is_preprint":false},{"pmid":"30871004","id":"PMC_30871004","title":"CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30871004","citation_count":21,"is_preprint":false},{"pmid":"33089764","id":"PMC_33089764","title":"Circ_0000215 Increases the Expression of CXCR2 and Promoted the Progression of Glioma Cells by Sponging miR-495-3p.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33089764","citation_count":21,"is_preprint":false},{"pmid":"36622345","id":"PMC_36622345","title":"Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/36622345","citation_count":20,"is_preprint":false},{"pmid":"39113226","id":"PMC_39113226","title":"Neutrophils Recruited by NKX2-1 Suppression via Activation of CXCLs/CXCR2 Axis Promote Lung Adenocarcinoma Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39113226","citation_count":19,"is_preprint":false},{"pmid":"36311783","id":"PMC_36311783","title":"CXCR2 intrinsically drives the maturation and function of neutrophils in mice.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36311783","citation_count":19,"is_preprint":false},{"pmid":"24555661","id":"PMC_24555661","title":"CXCR2 modulators: a patent review (2009 - 2013).","date":"2014","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/24555661","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55590,"output_tokens":10443,"usd":0.161708,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20644,"output_tokens":5269,"usd":0.117472,"stage2_stop_reason":"end_turn"},"total_usd":0.27918,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCR2 knockdown alleviates both replicative and oncogene-induced senescence (OIS) in primary human fibroblasts, while ectopic CXCR2 expression induces premature senescence via a p53-dependent mechanism. Cells undergoing OIS secrete multiple CXCR2-binding chemokines (e.g., IL-8, GROα) regulated by NF-κB and C/EBPβ transcription factors, and coordinately upregulate CXCR2, establishing an autocrine/paracrine senescence-reinforcing secretory network.\",\n      \"method\": \"shRNA screen in primary human fibroblasts, ectopic overexpression, p53 pathway analysis, NF-κB/C/EBPβ transcription factor analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal loss-of-function and gain-of-function with defined molecular pathway (p53, NF-κB, C/EBPβ), replicated across multiple senescence models\",\n      \"pmids\": [\"18555777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCR2 forms constitutive homodimers in a ligand-independent manner; the region between amino acids Ala-106 and Lys-163 is required for homodimerization. Truncated CXCR2 mutants that disrupt homodimerization impair receptor signaling and chemotaxis, establishing that CXCR2 functions as a dimer. CXCR1 does not dimerize with CXCR2.\",\n      \"method\": \"Co-immunoprecipitation of GFP- and V5-tagged CXCR2, truncation/deletion mutagenesis, functional assays (calcium signaling, chemotaxis) in HEK293 cells and cerebellar neurons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with defined domain, co-IP in multiple cell types, functional consequences validated\",\n      \"pmids\": [\"12888558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"β-arrestin-2 is a negative regulator of CXCR2 signaling in vivo. Deletion of β-arrestin-2 in mice increases CXCR2-mediated Ca2+ mobilization, superoxide anion production, and GTPase activity in neutrophils, while decreasing receptor internalization. β-arrestin-2 deficiency also enhances neutrophil recruitment to CXCL1 in vivo and accelerates wound re-epithelialization.\",\n      \"method\": \"β-arrestin-2 knockout mouse model, Ca2+ mobilization assay, receptor internalization assay, GTPase assay, superoxide production assay, dorsal air pouch model, excisional wound healing model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts in vitro and in vivo, clear pathway placement\",\n      \"pmids\": [\"16210646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL8 monomer is more active than dimer for intracellular Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, and exocytosis via both CXCR1 and CXCR2. Receptor regulation differs: CXCR1 is more rapidly regulated (phosphorylation, desensitization, β-arrestin translocation, internalization) by the monomer, whereas CXCR2 responds similarly to both monomer and dimer for these regulatory activities. ERK phosphorylation is more sustained through CXCR2 than CXCR1.\",\n      \"method\": \"Trapped non-associating CXCL8 monomer (L25NMe) and non-dissociating dimer (R26C) tested on human neutrophils and RBL-2H3 cells stably expressing CXCR1 or CXCR2; Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, exocytosis, receptor phosphorylation, desensitization, β-arrestin translocation, internalization, ERK phosphorylation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — engineered ligand variants, multiple orthogonal functional assays, cell lines with defined receptor expression\",\n      \"pmids\": [\"19667085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LASP-1 (LIM and SH3 protein-1) is a novel binding partner of CXCR2 that co-immunoprecipitates and co-localizes with CXCR2 at the leading edge of migrating cells. The LIM domain of LASP-1 directly binds the carboxy-terminal domain (CTD) of CXCR2, with Ile323-Leu324 of the conserved LKIL motif on CXCR2-CTD identified as the binding site. Disruption of this interaction inhibits CXCR2-mediated chemotaxis and focal adhesion turnover involving Src, paxillin, PAK1, p130CAS and ERK1/2.\",\n      \"method\": \"Proteomic co-immunoprecipitation from neutrophil-like dHL-60 cells, co-localization by microscopy, direct binding assay, site-directed and deletion mutagenesis, dominant negative and knockdown approaches, chemotaxis assays, focal adhesion kinase pathway analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding confirmed by mutagenesis of specific residues, co-IP plus functional knockout, multiple downstream pathway readouts\",\n      \"pmids\": [\"20419088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IQGAP1 is a novel CXCR2-interacting protein identified by proteomics; amino acids 1-160 of IQGAP1 directly interact with the carboxyl-terminal domain of CXCR2. CXCR2 co-localizes with IQGAP1 at the leading edge of polarized neutrophils, and CXCL8 stimulation enhances IQGAP1 association with Cdc42, placing IQGAP1 as an essential component of the CXCR2 'chemosynapse'.\",\n      \"method\": \"Proteomics co-immunoprecipitation, direct binding assay (domain mapping), co-localization by immunofluorescence in human neutrophils and dHL-60 cells, CXCL8-stimulated signaling assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct domain interaction mapped, co-localization with functional context, single lab\",\n      \"pmids\": [\"21876773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAM17 (TACE) mediates ligand-independent, irreversible CXCR2 shedding/down-regulation from the surface of mouse and human neutrophils upon overt neutrophil activation by non-ligand stimuli, but not upon chemokine ligand binding. Blocking ADAM17 reduces CXCR2 down-regulation on circulating neutrophils and enhances neutrophil recruitment during acute inflammation in vivo.\",\n      \"method\": \"Selective ADAM17 inhibitor, ADAM17 function-blocking antibody, ADAM17 gene-targeted mice, CXCR2 surface expression assay, in vivo acute inflammation model with CXCR2 inhibitor reversal\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacologic tools, multiple orthogonal approaches (inhibitor, antibody, KO mice), functional in vivo validation\",\n      \"pmids\": [\"25412626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCRL2, an atypical chemokine receptor, constitutively forms heterodimers with CXCR2 on neutrophils. CCRL2 heterodimerization regulates CXCR2 membrane expression and promotes CXCR2 functions including activation of β2-integrins. CCRL2-deficient mice show defective neutrophil recruitment and are protected in two models of inflammatory arthritis.\",\n      \"method\": \"Co-immunoprecipitation (heterodimer detection), CCRL2 knockout mouse model, in vitro β2-integrin activation assay, in vivo inflammatory arthritis models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP for heterodimerization, KO mouse phenotype in multiple disease models, functional β2-integrin readout\",\n      \"pmids\": [\"28743719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCR2-driven activation of NLRP3 inflammasome in macrophages proceeds via a protein kinase Cμ-dependent integrin-linked kinase (ILK) pathway. CXCL1 and CXCL2 signaling through CXCR2 enhances NLRP3 inflammasome activation and subsequent bioactive IL-1β production; blocking ILK or PKCμ by siRNA or pharmacological inhibitors compromises inflammasome activation.\",\n      \"method\": \"siRNA knockdown of CXCR2, ILK, PKCμ; pharmacological inhibitors; NLRP3 inflammasome activation assays; in vivo mouse models of carrageenan-induced inflammation; in vivo M. tuberculosis infection model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (siRNA) and pharmacologic dissection of pathway, multiple orthogonal in vitro and in vivo models\",\n      \"pmids\": [\"28739876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PPARγ transcriptionally activates CXCR2 expression in human macrophages by binding a PPAR response element (PPRE) in the CXCR2 promoter, increasing CXCR2 mRNA and membrane protein. PPARγ ligand-induced CXCR2 upregulation confers responsiveness to CXCR2 ligands (IL-8, GROβ) as measured by superoxide anion production.\",\n      \"method\": \"EMSA, ChIP, transient transfection/promoter assays, PPARγ ligand treatment of primary human macrophages; flow cytometry for membrane protein; superoxide production assay\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — PPRE binding confirmed by EMSA and ChIP, promoter transactivation assay, functional signaling readout\",\n      \"pmids\": [\"18292390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKCα activation in keratinocytes drives CXCR2-dependent neutrophil infiltration into the epidermis through NF-κB-dependent production of KC (CXCL1) and MIP-2 (CXCL2). Genetic ablation of CXCR2 in transgenic PKCα-overexpressing mice, or neutralizing antibodies against KC or MIP-2, prevents neutrophil infiltration. Systemic neutrophilia is mediated by G-CSF independently of CXCR2.\",\n      \"method\": \"Transgenic mouse model (K5-PKCα), CXCR2 knockout, neutralizing antibodies against KC/MIP-2, NF-κB pathway analysis, in vitro keratinocyte culture\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic CXCR2 ablation plus neutralizing antibody approaches, NF-κB mechanism established, in vivo and in vitro\",\n      \"pmids\": [\"16964312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCR2 is constitutively expressed on oligodendrocytes in the CNS, while its ligand CXCL1 is induced on astrocytes by IL-1β. In human fetal astrocyte cultures, IL-1β stimulation drives high-level CXCL1 synthesis. This CXCR2/CXCL1 signaling provides a mechanism for recruitment of oligodendrocytes to areas of demyelination in multiple sclerosis.\",\n      \"method\": \"Immunohistochemistry of MS lesions, in vitro human fetal astrocyte and oligodendrocyte cultures, IL-1β stimulation assay, protein expression analysis\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — in vitro stimulation assay with human cells, IHC in human tissue, but no direct functional migration assay for oligodendrocytes\",\n      \"pmids\": [\"16086366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CXCR2 expressed on resident lung cells (not on migrating mast cell progenitors themselves) is required for antigen-induced mast cell progenitor (MCp) recruitment to the lung and subsequent intraepithelial mast cell levels. CXCR2 deficiency reduces VCAM-1 transcripts and endothelial surface expression, linking CXCR2 signaling to regulation of endothelial VCAM-1 that is required for MCp migration.\",\n      \"method\": \"CXCR2-deficient mice, bone marrow reconstitution experiments (reciprocal BM transfers between WT and CXCR2-/- mice), anti-α4 integrin blocking mAb, VCAM-1 mRNA and surface protein quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal bone marrow reconstitution establishes cell-specific requirement, VCAM-1 mechanism directly measured, multiple experimental controls\",\n      \"pmids\": [\"18077323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCR2 and its ligands KC/CXCL1 and MIP-2/CXCL2/3 mediate neutrophil sequestration and lung injury in ventilator-induced lung injury (VILI). In vivo inhibition of CXCR2/CXC chemokine ligand interactions markedly reduces neutrophil sequestration and lung injury, confirmed in CXCR2-/- mice.\",\n      \"method\": \"Murine VILI model, in vivo anti-CXCR2 antibody blockade, CXCR2-/- mice, neutrophil counts, lung injury scoring\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout confirms pharmacologic blockade result, defined mechanistic pathway in vivo\",\n      \"pmids\": [\"12464676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-8-mediated migration of liver cancer cells (Huh-7 and HepG2) occurs via both CXCR1 and CXCR2; pretreatment with anti-CXCR1 or anti-CXCR2 antibodies markedly inhibits IL-8-directed cell migration in vitro.\",\n      \"method\": \"In vitro wound healing assay, migration assay, receptor-blocking antibodies against CXCR1 and CXCR2\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, receptor-blocking antibody approach, standard migration assays only\",\n      \"pmids\": [\"31516616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCR2 promotes ovarian cancer cell cycle progression by modulating p21(waf1/cip1), cyclin D1, CDK6, CDK4, cyclin A, and cyclin B1; inhibits apoptosis by suppressing p-p53/Puma/Bcl-xS and activating Bcl-xL/Bcl-2; and stimulates angiogenesis by increasing VEGF and decreasing thrombospondin-1 through MAPK and NF-κB pathways. These effects were established by stable shRNA knockdown of CXCR2.\",\n      \"method\": \"Stable shRNA knockdown of CXCR2 in ovarian cancer cell lines, Western blot for cell cycle proteins and apoptosis markers, EMSA for NF-κB, ELISA for VEGF/thrombospondin-1, flow cytometry, mouse xenograft model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable genetic knockdown with multiple downstream pathway readouts, in vivo validation, single lab\",\n      \"pmids\": [\"20505188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CMV-encoded vCXCL1 (UL146 gene product) acts as a highly efficacious agonist on both CXCR1 and CXCR2 with affinities of 44 nM and 5.6 nM respectively, activating calcium mobilization, phosphatidylinositol turnover, and chemotaxis. vCXCL1 does not activate or block the other 16 classified human chemokine receptors.\",\n      \"method\": \"Calcium mobilization assay, competition binding against radiolabeled CXCL8, inositol triphosphate turnover, chemotaxis assay using CXCR1- and CXCR2-expressing CHO, 300.19, COS7, and L1.2 cells; panel of 18 human chemokine receptors screened\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — comprehensive receptor panel screen, multiple functional assays, quantitative binding affinities determined\",\n      \"pmids\": [\"20044480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Extracellular DEK protein regulates hematopoietic stem cell (HSC) numbers and self-renewal through CXCR2 and heparan sulfate proteoglycans (HSPGs), with downstream activation of ERK1/2, AKT, and p38 MAPK. CXCR2-/- mice, CXCR2-blocking antibodies, and HSPG inhibitors all abolish DEK-mediated effects on HSC/HPC numbers.\",\n      \"method\": \"Cxcr2-/- mice, blocking CXCR2 antibodies, 3 different HSPG inhibitors, flow cytometry, transplantation assays, colony formation assays, phosphorylation assays (ERK1/2, AKT, p38 MAPK); DEK mutants lacking nuclear translocation signal or DNA-binding domain\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus multiple pharmacologic inhibitors, multiple orthogonal functional readouts including transplantation, signaling pathway mapped\",\n      \"pmids\": [\"31107242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR2 deficiency in the myeloid compartment (confirmed by bone marrow reconstitution) prevents CD11b+Ly6Ghi MDSC trafficking to tumor sites in rhabdomyosarcoma, establishing that CXCR2 on MDSCs mediates local immunosuppression that limits checkpoint blockade efficacy.\",\n      \"method\": \"CXCR2-deficient mice, anti-CXCR2 monoclonal antibody therapy, adoptive transfer/bone marrow reconstitution, flow cytometry for MDSC characterization, anti-PD1 combination therapy\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacologic CXCR2 ablation, adoptive transfer to define cell-autonomous requirement, defined immunosuppression phenotype\",\n      \"pmids\": [\"24848257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL8-induced chemotaxis via CXCR2 requires PI3K/Akt signaling and Cbl phosphorylation; Cbl and Akt regulate CXCR2-mediated chemotaxis. PI3K associates with Cbl upon CXCL8 stimulation. Kinase-dead Akt mutant decreases CXCR2-mediated chemotaxis and Cbl phosphorylation. Proteasome inhibition blocks CXCL8-induced internalization of CXCR2.\",\n      \"method\": \"CXCR2-overexpressing L1.2 cells, PI3K inhibitor (LY294002), tyrosine kinase inhibitor, proteasome inhibitors, overexpression of WT and mutant Cbl/Akt constructs, co-immunoprecipitation of PI3K p85 with Cbl, chemotaxis assay, internalization assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative mutants and pharmacologic inhibitors, co-IP, multiple functional readouts; single lab\",\n      \"pmids\": [\"16798838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL5 and CXCL8 activate CXCR2 on human brain endothelial cells (hCMEC/D3), causing Akt/PKB phosphorylation, redistribution of tight junction ZO-1, actin stress fiber formation, and decreased paracellular barrier function. CXCR2 expression is inflammation-inducible on brain endothelium, and selective CXCR2 antagonism (SB332235) partially prevents chemokine-induced tight junction disruption.\",\n      \"method\": \"Human cerebral microvascular endothelial cell line hCMEC/D3, recombinant CXCL5/CXCL8 treatment, real-time electrical impedance sensing for barrier function, immunofluorescence for ZO-1 and actin, Western blot for Akt phosphorylation, selective CXCR2 antagonist SB332235, IHC of human MS brain biopsies\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional barrier assay with pharmacologic antagonist rescue, mechanistic signaling (Akt) and structural (ZO-1) readouts, single lab\",\n      \"pmids\": [\"30704100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCR2 in CXCR2(+)CD11b(+)Ly6Ghi MDSCs is required for their trafficking to pancreatic tumors; genetic ablation of CXCR2 abrogates metastasis, and combined CXCR2 inhibition with anti-PD1 significantly extends survival in established pancreatic cancer disease.\",\n      \"method\": \"Genetic ablation and pharmacologic inhibition of CXCR2 in KPC mouse model, neutrophil/MDSC depletion, flow cytometry for T cell infiltration, anti-PD1 combination therapy, survival analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacologic CXCR2 ablation, cell depletion, defined metastatic phenotype with mechanistic cell-type assignment\",\n      \"pmids\": [\"27265504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cxcl2 variants are more potent than Cxcl1 variants for Cxcr2 G-protein and β-arrestin receptor activation, while native Cxcl1 and its dimers bind heparan sulfate (HS) glycosaminoglycans with higher affinity than Cxcl2 variants. Peritoneal neutrophil recruitment cannot be solely attributed to Cxcr2 activation or GAG interactions alone, and their relationship is highly context-dependent.\",\n      \"method\": \"Cxcr2 G-protein and β-arrestin activity assays, GAG heparan sulfate binding assay, peritoneal neutrophil recruitment assay, flow cytometry for Cxcr2 and CD11b on neutrophils, engineered trapped dimer variants of Cxcl1 and Cxcl2\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — engineered ligand variants, in vitro receptor activity assays, in vivo recruitment assays with multiple conditions\",\n      \"pmids\": [\"32881070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NMR and molecular dynamics reveal that CXCL7 forms heterodimers with CXCL1 and CXCL4 through packing interactions, while electrostatic repulsion disfavors CXCL7-CXCL8 heterodimer. A disulfide-trapped CXCL7-CXCL1 heterodimer is highly active in Ca2+ release assay via CXCR2 but GAG (heparin) binding to the heterodimer prevents receptor binding, suggesting GAG interactions regulate heterodimer function.\",\n      \"method\": \"Solution NMR spectroscopy, molecular dynamics simulation, disulfide-linked trapped heterodimer engineering, Ca2+ release assay (CXCR2 activation), heparin binding studies\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with engineered trapped heterodimer and functional Ca2+ assay, mechanistic insight into GAG vs receptor binding\",\n      \"pmids\": [\"28368308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCR2 on bone marrow stroma (in addition to granulocytes) is involved in HSPC localization and egress; combined targeting of CXCR2 (agonist) and VLA4 integrin achieves rapid, synergistic mobilization of HSPCs including true HSCs in mice.\",\n      \"method\": \"CXCR2 agonist administration, VLA4 inhibitor, mechanistic studies using CXCR2 expressed on BM stroma vs granulocytes, HSPC flow cytometry, in vivo mobilization assays in mice\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mechanistic studies distinguishing stromal vs granulocyte CXCR2 contributions, single lab\",\n      \"pmids\": [\"31085833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCR2 supports nociceptive sensitization after traumatic brain injury (TBI) through an epigenetic mechanism: TBI enhances association of the CXCR2 promoter with acetylated-H3K9 histone (assessed by ChIP), leading to spinal cord CXCR2 upregulation in neurons. Systemic or intrathecal CXCR2 antagonist (SCH527123) reverses hindpaw allodynia after TBI.\",\n      \"method\": \"Rat lateral fluid percussion TBI model, chromatin immunoprecipitation (ChIP) for H3K9 acetylation at CXCR2 promoter, CXCR2 antagonist (SCH527123) systemic and intrathecal administration, immunohistochemistry, Western blot, ELISA for CXCL1\",\n      \"journal\": \"Molecular pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishes epigenetic mechanism at CXCR2 promoter, pharmacologic antagonism confirms functional role, single lab\",\n      \"pmids\": [\"28845733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL1/CXCR2 signaling in the hippocampus contributes to chronic stress-induced depression in mice; CXCR2 inhibition (SB265610) prevents chronic stress-induced depression-like behaviors, inhibits GSK3β activity, blocks apoptosis pathways (reduced caspase-3, Bax), and restores BDNF and CREB expression. Intrahippocampal CXCL1 overexpression activates GSK3β and suppresses CREB/BDNF.\",\n      \"method\": \"Unpredictable chronic mild stress (UCMS) mouse model, intrahippocampal microinjection of lenti-CXCL1, CXCR2 inhibitor SB265610, GSK3β inhibitor AR-A014418, Western blot for caspase-3/Bax/CREB/BDNF, behavioral assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lentiviral gain-of-function and pharmacologic inhibition, defined molecular pathway (GSK3β-caspase-BDNF), single lab\",\n      \"pmids\": [\"31034777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NMR structural analysis shows that tick salivary protein Evasin-3 disrupts the glycosaminoglycan-binding site of CXCL8 and inhibits CXCL8 interaction with CXCR2. Synthetic Evasin-3 variants effectively inhibit CXCL8-induced migration of polymorphonuclear neutrophils.\",\n      \"method\": \"Solution NMR spectroscopy of Evasin-3/CXCL8 complex, surface plasmon resonance for binding affinity, neutrophil migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure defines binding interface at CXCR2-binding site of CXCL8, functional validation by migration assay\",\n      \"pmids\": [\"31235521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8/CXCR2 signaling drives bone marrow fibrosis in myelofibrosis; CXCL8 promotes proliferation and fitness of MF hematopoietic stem/progenitor cells in vitro. Genetic deletion of Cxcr2 in a murine MF model abrogates fibrosis and extends overall survival; pharmacologic CXCR1/2 pathway inhibition improves hematologic parameters, attenuates fibrosis, and synergizes with JAK inhibitor therapy.\",\n      \"method\": \"Single-cell transcriptomics, cytokine secretion studies in primary MF patient cells, hMPLW515L murine adoptive transfer model with Cxcr2 genetic deletion, pharmacologic CXCR1/2 inhibitor, JAK inhibitor combination, in vitro proliferation with exogenous CXCL8\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion in disease model, pharmacologic inhibition, patient primary cells, multiple orthogonal functional readouts\",\n      \"pmids\": [\"36800567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR2 signaling in KRASG12D-bearing pancreatic ductal cells mediates autocrine tumor cell proliferation; knockdown or pharmacological inhibition of CXCR2 reduces in vitro and in vivo tumor cell proliferation. Importantly, both genetic and pharmacological CXCR2 inhibition reduces KRAS protein levels, revealing a KRAS-CXCR2 feed-forward loop.\",\n      \"method\": \"CXCR2 knockdown in human KRAS(G12D)-bearing pancreatic duct-derived cells, CXCR2 antagonists (pharmacologic), in vitro proliferation assays, in vivo tumor growth, KRAS protein quantification by Western blot, Pdx1-cre;LSL-Kras(G12D) mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacologic evidence for feed-forward loop, in vivo validation, single lab\",\n      \"pmids\": [\"26771140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCR2 deficiency in Cxcr2 knockout mice decreases the percentage of mature neutrophils in spleen, increases aged CD62Llo CXCR4hi neutrophils in spleen, reduces phagocytic ability and reactive oxygen species production of spleen neutrophils, reduces F-actin and α-tubulin levels, and impairs ERK1/2, p38 MAPK, PI3K-AKT, NF-κB, TGFβ and IFNγ signaling pathways in neutrophils.\",\n      \"method\": \"Cxcr2 knockout mice, flow cytometry, phagocytosis assay, ROS production assay, F-actin/α-tubulin quantification, Western blot for signaling pathways\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comprehensive genetic KO analysis with multiple functional and signaling readouts, single lab\",\n      \"pmids\": [\"36311783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCL2-CXCR2 signaling mediates colon cancer cell adhesion to extracellular matrix proteins (vitronectin, fibronectin, fibrinogen) in a CXCR2-dependent manner, and this adhesion requires αV integrin. In vivo, CXCR2 antagonism reduces peritoneal metastatic nodules by 70%, and αV integrin immunoneutralization reduces nodules by 69%, placing CXCL2-CXCR2 upstream of αV integrin in peritoneal metastasis.\",\n      \"method\": \"CXCR2 antagonist SB225002, αV integrin-blocking antibody, in vitro ECM adhesion assay, in vivo peritoneal metastasis mouse model (laparotomy + CT-26 cells), gene expression analysis of CXCL2\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and antibody-based pathway epistasis, in vitro mechanism with in vivo validation, single lab\",\n      \"pmids\": [\"34115261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL5-CXCR2 signaling constitutes a senescence-associated secretory phenotype (SASP) in aging mouse and human embryos; CXCL5 treatment of young mouse embryos decreases implantation rates and increases expression of aging markers (P53, P21, PAI-1, IL-6). Suppression of CXCL5-CXCR2 signaling in aging mouse embryos by neutralizing antibodies or receptor antagonist improves implantation rate and pregnancy outcomes.\",\n      \"method\": \"Microarray analysis of aging human blastocysts, mouse embryo culture with recombinant CXCL5, CXCR2 antagonist, CXCL5 neutralizing antibody, implantation assays, pregnancy and delivery outcomes, gene expression analysis\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and antibody inhibition with functional reproductive outcomes, aging marker quantification, single lab\",\n      \"pmids\": [\"32959976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2 (PTGS2). Mechanistically, CXCR2 promotes EMT, anti-apoptosis, and anti-senescence of breast cancer cells, with AKT1 and COX2 acting as downstream mediators inversely controlling these phenotypes.\",\n      \"method\": \"CXCR2 overexpression/knockdown in breast cancer cell lines, Western blot for AKT1, COX2, EMT markers, apoptosis markers, senescence assays, correlation with clinical tissue data\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanism inferred from expression correlation and knockdown/overexpression without direct receptor-pathway reconstitution\",\n      \"pmids\": [\"28964785\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCR2 is a G protein-coupled chemokine receptor that functions as a constitutive homodimer (requiring residues Ala-106 to Lys-163) and can heterodimerize with CCRL2 to regulate its surface expression and β2-integrin activation; upon binding ELR+ CXC chemokines (particularly CXCL8 monomer > dimer for most activities), it signals through Gα proteins to mobilize Ca2+, activate PI3K/AKT, ERK1/2, and p38 MAPK; β-arrestin-2 negatively regulates CXCR2 signaling by promoting receptor internalization, while ADAM17 mediates irreversible, ligand-independent CXCR2 shedding; intracellularly, CXCR2 assembles a 'chemosynapse' with scaffolding proteins LASP-1 (binding the LKIL motif on the C-terminal domain) and IQGAP1 to drive directed chemotaxis and focal adhesion turnover; CXCR2 is transcriptionally induced by PPARγ (via a PPRE in its promoter), NF-κB, and epigenetic H3K9 acetylation; it drives neutrophil recruitment to sites of inflammation, mediates MDSC trafficking to tumors, activates NLRP3 inflammasome via PKCμ-ILK, regulates endothelial VCAM-1 to control mast cell progenitor recruitment, reinforces cellular senescence via a p53-dependent autocrine/paracrine loop involving NF-κB/C/EBPβ-regulated CXCR2-binding chemokines, and supports KRAS-driven pancreatic cancer through an oncogene feed-forward loop.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCR2 is a G protein-coupled chemokine receptor for ELR+ CXC chemokines (CXCL1/2/5 and CXCL8/IL-8) that drives directed cell migration, most prominently neutrophil recruitment to sites of inflammation [#13, #10]. It functions as a constitutive, ligand-independent homodimer, with the region between Ala-106 and Lys-163 required for dimerization and for productive signaling and chemotaxis [#1], and it additionally forms constitutive heterodimers with the atypical receptor CCRL2 that regulate its surface expression and enable β2-integrin activation [#7]. Ligand discrimination is encoded at the protein level: the CXCL8 monomer is more active than the dimer for Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis and exocytosis, and CXCR2 produces more sustained ERK phosphorylation than CXCR1 [#3], while CXCL2 variants are more potent than CXCL1 for G-protein and β-arrestin activation [#22]. Downstream, CXCR2 signals through PI3K/Akt (with Cbl phosphorylation required for chemotaxis) and through ERK1/2 and p38 MAPK [#19, #30], and assembles an intracellular 'chemosynapse' in which LASP-1 binds the LKIL motif (Ile323-Leu324) of the receptor C-terminal domain and IQGAP1 (residues 1-160) engages the same CTD to couple the receptor to Cdc42, focal adhesion turnover and leading-edge polarization [#4, #5]. Receptor output is negatively regulated by β-arrestin-2, which promotes internalization and dampens Ca2+, superoxide and GTPase responses [#2], and CXCR2 is irreversibly removed from the surface by ADAM17-mediated, ligand-independent shedding upon non-chemokine neutrophil activation [#6]. Its expression is transcriptionally controlled by PPARγ via a promoter PPRE [#9], by NF-κB-driven chemokine circuits [#10], and by H3K9 acetylation at its promoter [#25]. Through these mechanisms CXCR2 governs neutrophil and MDSC trafficking and immunosuppression in tumors [#18, #21], reinforces p53-dependent oncogene-induced senescence via an autocrine NF-κB/C/EBPβ chemokine loop [#0], and sustains a KRAS-CXCR2 feed-forward loop in pancreatic cancer [#29].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the receptor's quaternary structure: it answered whether CXCR2 acts as a monomer or oligomer by showing it forms ligand-independent constitutive homodimers required for signaling.\",\n      \"evidence\": \"Co-IP of differentially tagged CXCR2 plus truncation mutagenesis mapping a Ala-106 to Lys-163 dimerization region, with Ca2+ and chemotaxis readouts in HEK293 cells and neurons\",\n      \"pmids\": [\"12888558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure of the dimer interface\", \"Whether dimerization state is dynamically regulated by ligand or expression level not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed β-arrestin-2 as the in vivo brake on CXCR2, resolving how the receptor is desensitized and internalized during neutrophil responses.\",\n      \"evidence\": \"β-arrestin-2 knockout mice with Ca2+, superoxide, GTPase, internalization assays and in vivo neutrophil recruitment/wound healing\",\n      \"pmids\": [\"16210646\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites recruiting β-arrestin-2 not mapped here\", \"Distinction between arrestin scaffolding vs desensitization roles unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined an upstream transcriptional input by showing PPARγ directly activates CXCR2 expression, linking nuclear receptor signaling to chemokine responsiveness.\",\n      \"evidence\": \"EMSA/ChIP of a PPRE in the CXCR2 promoter, promoter assays and superoxide readout in primary human macrophages\",\n      \"pmids\": [\"18292390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cooperating transcription factors at the promoter not defined\", \"Physiological context driving PPARγ-dependent induction unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected CXCR2 to cell-autonomous senescence, showing it is both necessary and sufficient to reinforce oncogene-induced senescence through a p53-dependent autocrine chemokine network.\",\n      \"evidence\": \"shRNA screen and ectopic overexpression in primary human fibroblasts with p53 and NF-κB/C/EBPβ pathway analysis\",\n      \"pmids\": [\"18555777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct receptor-to-p53 signaling intermediates not mapped\", \"Whether autocrine chemokine identity determines senescence strength untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed that ligand oligomeric state encodes signaling bias, distinguishing CXCR2 from CXCR1 in regulation and ERK kinetics.\",\n      \"evidence\": \"Trapped CXCL8 monomer (L25NMe) and dimer (R26C) variants on neutrophils and RBL-2H3 cells expressing CXCR1 or CXCR2, multiple functional and regulatory assays\",\n      \"pmids\": [\"19667085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for differential CXCR1/CXCR2 regulation not resolved\", \"In vivo relevance of monomer/dimer bias not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified the molecular scaffold of directed migration by mapping a direct LASP-1 interaction to the CXCR2 C-terminal LKIL motif controlling chemotaxis and focal adhesion turnover.\",\n      \"evidence\": \"Proteomic co-IP, direct binding with residue-level mutagenesis (Ile323-Leu324), co-localization and FAK pathway analysis in dHL-60 neutrophil-like cells\",\n      \"pmids\": [\"20419088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the chemosynapse not defined\", \"Whether LASP-1 binding is regulated by receptor phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended the chemosynapse model by adding IQGAP1 as a direct CTD partner linking the receptor to Cdc42 at the leading edge.\",\n      \"evidence\": \"Proteomic co-IP, domain mapping (IQGAP1 aa 1-160), co-localization and CXCL8-stimulated Cdc42 association in human neutrophils\",\n      \"pmids\": [\"21876773\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without reciprocal validation in other systems\", \"Order of LASP-1 vs IQGAP1 assembly on the CTD unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined an irreversible, ligand-independent off-switch by identifying ADAM17 as the protease that sheds CXCR2 upon non-chemokine neutrophil activation.\",\n      \"evidence\": \"ADAM17 inhibitor, blocking antibody and gene-targeted mice with surface expression and in vivo acute inflammation readouts\",\n      \"pmids\": [\"25412626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage site on CXCR2 not mapped\", \"Signals triggering ADAM17 activation toward CXCR2 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated cell-autonomous CXCR2 requirement in myeloid MDSCs for tumor trafficking and immunosuppression that limits checkpoint blockade.\",\n      \"evidence\": \"CXCR2-deficient mice, anti-CXCR2 antibody, bone marrow reconstitution and anti-PD1 combination in rhabdomyosarcoma\",\n      \"pmids\": [\"24848257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chemokine ligands recruiting MDSCs not specified here\", \"Whether MDSC CXCR2 signaling differs mechanistically from neutrophil signaling unaddressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified CCRL2 heterodimerization as a regulator of CXCR2 surface expression and β2-integrin activation, broadening the receptor's interaction repertoire.\",\n      \"evidence\": \"Co-IP, CCRL2 knockout mice, in vitro β2-integrin activation and inflammatory arthritis models\",\n      \"pmids\": [\"28743719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterodimer interface not mapped\", \"Mechanism by which CCRL2 alters CXCR2 signaling bias unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked CXCR2 to innate inflammasome output by placing PKCμ-ILK between the receptor and NLRP3 activation in macrophages.\",\n      \"evidence\": \"siRNA and pharmacologic inhibition of CXCR2/ILK/PKCμ with inflammasome assays and in vivo carrageenan and M. tuberculosis models\",\n      \"pmids\": [\"28739876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link from receptor to PKCμ not established\", \"G protein coupling to this pathway not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a KRAS-CXCR2 feed-forward loop in pancreatic ductal cells where receptor inhibition lowers KRAS protein, defining an oncogenic autocrine circuit.\",\n      \"evidence\": \"CXCR2 knockdown and antagonists in KRAS(G12D) pancreatic duct cells, KRAS Western blot and Pdx1-cre;LSL-Kras(G12D) mice\",\n      \"pmids\": [\"26771140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CXCR2 stabilizes KRAS protein unknown\", \"Single-lab finding without orthogonal confirmation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided structural insight into ligand regulation by GAGs, showing chemokine heterodimer formation and heparin binding modulate CXCR2 receptor engagement.\",\n      \"evidence\": \"Solution NMR and MD with disulfide-trapped CXCL7-CXCL1 heterodimer and Ca2+ release assays; separately, Evasin-3 NMR mapping of the CXCL8 GAG/CXCR2-binding site with neutrophil migration assays\",\n      \"pmids\": [\"28368308\", \"31235521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-structure of chemokine bound to CXCR2 itself\", \"In vivo significance of heterodimer-GAG competition not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed CXCR2 in hematopoietic stem cell regulation, showing extracellular DEK acts through CXCR2 and HSPGs to control HSC self-renewal via ERK/AKT/p38.\",\n      \"evidence\": \"Cxcr2-/- mice, blocking antibodies, HSPG inhibitors, transplantation, colony and phosphorylation assays with DEK mutants\",\n      \"pmids\": [\"31107242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DEK is a direct CXCR2 agonist not biochemically established\", \"Relative contribution of HSPG vs CXCR2 binding not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established CXCR2 as a disease driver in myelofibrosis, where CXCL8/CXCR2 promotes malignant HSPC fitness and fibrosis and synergizes with JAK inhibition.\",\n      \"evidence\": \"Single-cell transcriptomics, primary MF patient cells, hMPLW515L murine model with Cxcr2 deletion, CXCR1/2 and JAK inhibitor combination\",\n      \"pmids\": [\"36800567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-of-origin for pathogenic CXCR2 signaling not fully resolved\", \"Direct downstream effectors of fibrosis induction not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct CXCR2 signaling outputs (G-protein vs β-arrestin, homodimer vs CCRL2 heterodimer, monomer vs dimer ligand) are integrated to specify divergent cellular outcomes — chemotaxis, senescence, inflammasome activation, KRAS stabilization — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of CXCR2 in its dimeric/heterodimeric states\", \"Biased agonism rules across ligands not systematically defined\", \"Mechanistic links from receptor to non-canonical outputs (KRAS protein levels, p53) not biochemically traced\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 16, 22]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 6, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 8, 13, 18]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [21, 28, 29]}\n    ],\n    \"complexes\": [\n      \"CXCR2 homodimer\",\n      \"CXCR2-CCRL2 heterodimer\",\n      \"CXCR2 chemosynapse (with LASP-1 and IQGAP1)\"\n    ],\n    \"partners\": [\n      \"CCRL2\",\n      \"LASP1\",\n      \"IQGAP1\",\n      \"ARRB2\",\n      \"ADAM17\",\n      \"CDC42\",\n      \"CXCL8\",\n      \"CXCL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}